Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV randomized double-blind active-controlled study of 23-valent pneumococcal polysaccharide vaccine in people aged 2 years and older
CTR20222149Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Sinovac Biotech Ltd.. Started Sep 2022; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20222149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222149.